Carregant...
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study
Although immune checkpoint inhibitor therapy has led to modest response rates in patients with advanced urothelial cancer, the combination of chemotherapy with immune checkpoint inhibition has not been previously clinically studied. In this phase I study, we found that the combination of pembrolizum...
Guardat en:
| Publicat a: | Clin Genitourin Cancer |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6450697/ https://ncbi.nlm.nih.gov/pubmed/30166228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.07.004 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|